OOIR: Observatory of International Research

Papers

(The TQCC of Journal of Comparative Effectiveness Research is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Cost–effectiveness of pembrolizumab for second-line treatment of esophageal squamous cell carcinoma patients with a combined positive score of 10 or more	174
Acute effects of resistance exercise with blood flow restriction on cardiovascular response: a meta-analysis	46
Postoperative outcomes and anesthesia type in total knee arthroplasty in patients with obstructive sleep apnea	45
Economic burden of sickle cell disease in the United States: a retrospective analysis of a commercial insurance database	35
Journal of Comparative Effectiveness Research : 2022 year in review	30
Smart connected insulin dose monitoring technologies versus standard of care: a Canadian cost–effectiveness analysis	26
Effect of home-based exercise programs with e-devices on falls among community-dwelling older adults: a meta-analysis	25
Engaging veterans in the research process: a practical guide	23
Long-term effectiveness and safety of ravulizumab in paroxysmal nocturnal hemoglobinuria: a plain language summary	23
MOMENT registry: Patients with advanced non-small-cell lung cancer harboring MET exon 14 skipping treated with systemic therapy	23
Atezolizumab with chemotherapy in first-line treatment for metastatic urothelial cancer: a cost–effectiveness analysis	23
An observational cohort study of pelvic floor photobiomodulation for treatment of chronic pelvic pain	22
Corrigendum	20
Access in all areas? A round-up of developments in market access and health technology assessment: part 10	20
Effectiveness and safety of asfotase alfa for people with hypophosphatasia: a plain language summary of three studies	19
R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 20	19
Comparative safety of B/F/TAF versus other antiretroviral therapy regimens for treatment-naïve people with HIV-1: a systematic literature review and network meta-analysis	18
Costs associated with nonalcoholic steatohepatitis disease progression in Medicare patients: a retrospective cohort study	18
Discharges against medical advice and 30-day healthcare costs: an analysis of commercially insured adults	16
Impact of surgical complications on hospital costs and revenues: retrospective database study of Medicare claims	16
Cost–effectiveness analysis of a resource-intensive approach versus minimally invasive strategy for high-risk transcatheter aortic valve replacement patients	16
The cost–effectiveness of pegcetacoplan in complement treatment-naïve adults with paroxysmal nocturnal hemoglobinuria in the USA	15
Clinical assessment of the potential use of a novel single-dose prefilled injection device for the administration of Acthar Gel in children: a narrative review	14
Lessons on the use of real-world data in medical device research: findings from the National Evaluation System for Health Technology Test-Cases	14
Cost of disease progression among US patients with human epidermal growth factor receptor 2-positive metastatic breast cancer	14

Ravulizumab in adults and children with atypical hemolytic uremic syndrome: a plain language summary of three studies	13
Time-limited reimbursement and Temporary Access Process for early access to oncology treatments in Canada: a perspective based on the epcoritamab experience	13
Clinical manifestations and healthcare utilization before diagnosis of transthyretin amyloidosis	12
Healthcare utilization and costs following molecular diagnostic testing among patients with vaginitis	12
Bayesian hierarchical model-based network meta-analysis to overcome survival extrapolation challenges caused by data immaturity	12
EU HTA Joint Clinical Assessment: are patients with rare disease going to lose out?	12
Cost–effectiveness of lung cancer screening with volume computed tomography in Portugal	12
Letter in reply	12
A real-world analysis of antidepressant medications in US veterans aged 60 years and older: a comparative analysis	11
R WE ready for reimbursement? A round up of developments in real-world evidence relating to HTA: part 3	11
Real-world ePRO use and clinical outcomes using electronic patient-reported symptom monitoring for patients with advanced non-small-cell lung cancer receiving first-line pembrolizumab	11
Corrigendum	11
Increasing transparency in indirect treatment comparisons: is selecting effect modifiers the missing part of the puzzle? A review of methodological approaches and critical considerations	11
Augmenting external control arms using Bayesian borrowing: a case study in first-line non-small cell lung cancer	10
Network meta-analysis for indirect comparison of lanadelumab and berotralstat for the treatment of hereditary angioedema	10
The triple win – implementation science benefits patients, healthcare systems and industry alike	10
Cost–effectiveness analysis of prolonged-release fampridine to treat walking disability of multiple sclerosis in China	10
Comparison of Enterprise stent 2 with 1 in assisting coiling of ruptured aneurysms: a real-world study	10
Ataluren delays loss of ambulation and respiratory decline in nonsense mutation Duchenne muscular dystrophy patients	10
Healthcare costs and resource utilization of patients with chronic post-traumatic stress disorder: a retrospective US claims analysis of commercially insured patients	10
Cost-utility of real-time continuous glucose monitoring versus self-monitoring of blood glucose in people with insulin-treated Type 2 diabetes in Canada	10
Real-world weight changes in people with HIV-1 at risk of weight gain (female, Black or Hispanic) switching from integrase strand transfer inhibitors	10
Effectiveness of tisagenlecleucel versus real-world standard of care in relapsed/refractory follicular lymphoma	9
Diversity in clinical trial inclusion for peripheral artery disease lower extremity endovascular interventions: a systematic review protocol	9
Characterization of medical device randomized controlled trials with adaptive designs	9
Ravulizumab for adults with generalized myasthenia gravis: a plain language summary of three studies	9
Letter to the editor: network meta-analysis for indirect comparison of lanadelumab and berotralstat for the treatment of hereditary angioedema	9
Healthcare resources and costs associated with nonvalvular atrial fibrillation in Spain: apixaban versus acenocoumarol	9
How the use of standardized protocols may paradoxically worsen disparities for safety-net hospitals	9
Dependent censoring bias assessment using inverse probability of censoring weights: Type 2 diabetes mellitus risk in patients initiating bisoprolol versus other antihypertensives in a Clinical Practic	9
Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancer	9
Impact of COVID-19 on chronic pain structures: data from French national survey	8
Tr14 gel for the treatment of acute ankle sprains: a plain language summary of the TRAUMED trial	8
Are indirect comparisons for treatments in migraine necessitas? Many inevitable challenges to overcome	8
Overall survival in the UK in mycosis fungoides or Sézary syndrome cutaneous T-cell lymphoma: comparative effectiveness of mogamulizumab versus current standard of care	8
Healthcare resource utilization and costs in pediatric pulmonary arterial hypertension in a third-level hospital in Mexico	8
Access in all areas? A round up of developments in market access and health technology assessment: part 1	8
Impact analysis of expanding narrow-spectrum antibiotic use for children with ear, sinus and throat infections	8
Rivaroxaban versus low-molecular-weight heparins for short- and long-term prognosis in patients with deep vein thrombosis after spontaneous intracranial hemorrhage	8
COVID-19 clinical trials: who is likely to participate and why?	8
Cost–utility analysis of single nucleotide polymorphism panel-based machine learning algorithm to predict risk of opioid use disorder	8
Does off-hours endoscopic hemostasis affect outcomes of nonvariceal upper gastrointestinal bleeding?	7
An impact evaluation of an education bundle for patients at risk of developing venous thromboembolism	7
Composite endpoints in health technology assessment: Part 1 – an illustration of best modeling practice	7
Efficacy and safety of PD-1/PD-L1 and CTLA-4 immune checkpoint inhibitors in colorectal cancer: a meta-analysis	7
Teclistamab versus real-world physician’s choice of therapy in triple-class exposed relapsed/refractory multiple myeloma	7
Corrigendum	7
Quality in qualitative evidence: new best practice principles from NICE’s real-world evidence framework	7
The effects of Pilates on pain, functionality, quality of life, flexibility and endurance in lumbar disc herniation	7
R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 10	7

Burden of illness for patients with primary biliary cholangitis: an observational study of clinical characteristics and healthcare resource utilization	7
Comparative effectiveness research in COVID-19 using real-world data: methodological considerations	7
An evaluation of stakeholder engagement in comparative effectiveness research: lessons learned from SWOG S1415CD	6
Cost–effectiveness of ensartinib for patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer in China	6
Navigating adalimumab biosimilars: an expert opinion	6
Treatment goals for rheumatoid arthritis: patient engagement and goal collection	6
Identification of treatment effect modifiers and prognostic factors in newly diagnosed and relapsed or refractory multiple myeloma	6
An economic evaluation of teledermatology care delivery for chronic skin diseases	6
Application of quantitative bias analysis for unmeasured confounding in cost–effectiveness modelling	6
Quantitative bias analysis for external control arms using real-world data in clinical trials: a primer for clinical researchers	6
Expanding the learning health system model to be health literate	6
A value-based budget impact model for dronedarone compared with other rhythm control strategies	6
Assessing the change in disease severity based on depressive symptoms in real-world psoriasis patients	6
Use of transportability methods for real-world evidence generation: a review of current applications	6
Evaluation of the treatment patterns among commercially insured patients with nonvalvular atrial fibrillation prescribed an oral anticoagulant by race/ethnicity	6
A systematic review of discounting in national health economic evaluation guidelines: healthcare value implications	6
The impact of lower limb chronic venous disease on quality of life: patient and physician perspectives	6
Once-nightly sodium oxybate (FT218) improved symptoms of disrupted nighttime sleep in people with narcolepsy: a plain language summary	6
Evaluating real-world COVID-19 vaccine effectiveness using a test-negative case–control design	6
COVID-19 complications in males and females: recent developments	5
Expert perspectives on the use of safinamide for Parkinson’s disease in Portugal: insights from a Portuguese Delphi Consensus	5
A systematic review of health-related quality of life outcomes in patients with advanced breast cancer treated with palbociclib	5
Adverse event costs of systemic therapies for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy and biologics in the US	5
In-hospital mortality in amyloid light chain amyloidosis: analysis of the Premier Healthcare Database	5
Clinical and economic burden among older adults with acromegaly in the United States	5
Cost–effectiveness of brentuximab vedotin for the treatment of cutaneous T-cell lymphoma	5
Robotic-assisted total hip arthroplasty: an economic analysis	5
The cost-effectiveness of real-time continuous glucose monitoring versus intermittently scanned continuous glucose monitoring in individuals with insulin-treated Type 2 diabetes mellitus in Canada	5
Economic impact of reduced postoperative visits after inflatable penile prosthesis implantation	5
R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 15	5
QDOT MICRO™ versus THERMOCOOL ^® SMARTTOUCH™ and THERMOCOOL SMARTTOUCH ^® Surround Flow in radiofrequency ablation of paroxysmal atr	5
Clinical and economic implications of focal dissection treatment following percutaneous transluminal angioplasty of the superficial femoral artery: an exploratory analysis based on the TOBA II Study	5
Safety and effectiveness of intranasal esketamine for treatment-resistant depression: a real-world retrospective study	5
Healthcare resource utilization, costs and treatment associated with myasthenia gravis exacerbations among patients with myasthenia gravis in the USA: a retrospective analysis of claims data	5
Mapping methods gaps between EU joint clinical assessments and local health technology assessment decision-making: an environmental scan of guidance in select EU markets and harmonization challenges	5
Structural hemodynamic valve deterioration durability of RESILIA-tissue versus contemporary aortic bioprostheses	5
Letter in Reply: indirect comparison of quality-of-life scores between patients with advanced breast cancer receiving palbociclib and abemaciclib in combination with fulvestrant	5
Vaginal laser therapy for gynecologic conditions: re-examining the controversy and where do we go from here	5
Economic burden of early-stage non-small-cell lung cancer: an assessment of healthcare resource utilization and medical costs	5
Navigating the unknown: how to best ‘reflect’ standard of care in indications without a dedicated treatment pathway in health technology assessment submissions	5
Healthcare utilization and costs among patients with acromegaly in the United States	4
Comparing the performance of two-stage residual inclusion methods when using physician's prescribing preference as an instrumental variable: unmeasured confounding and noncollapsibility	4
The effects of exercises with a Pilates ball on balance, reaction time and dual-task performance of kindergarten children	4
Evaluation of inpatient and emergency department healthcare resource utilization and costs pre- and post-nusinersen for the treatment of spinal muscular atrophy using United States claims	4
Impact of the COVID-19 pandemic on healthcare resource utilization across selected disease areas in the USA	4
Visualizing the target estimand in comparative effectiveness studies with multiple treatments	4
R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 4	4
How pharma can amplify product value with implementation science	4
A review of stakeholder recommendations for defining fit-for-purpose real-world evidence algorithms	4
Plain language summary: Clinical study of BI 1015550 as a potential treatment for idiopathic pulmonary fibrosis	4
Sex-based differences in the outcomes of patients with lung carcinoids	4
Safety of early postoperative showering in level-1 and level-2 surgical wounds: a retrospective study	4
Efficacy of CARVYKTI in CARTITUDE-4 versus other conventional treatment regimens for lenalidomide-refractory multiple myeloma using inverse probability of treatment weighting	4
Comparative effectiveness analysis between entrectinib clinical trial and crizotinib real-world data inROS1+ NSCLC	4
An international observational study assessing conservative management in hemorrhoidal disease: results of CHORALIS (aCute HemORrhoidal disease evALuation International Study)	4
Budget impact analyses of hemoglobin A1c and lipid panel point-of-care testing with Afinion™ 2 in Canada and Italy	4
Respiratory and nonrespiratory COVID-19 complications in patients with obesity: recent developments	4
Why, whether and how to use high-flow nasal therapy in acute exacerbations of chronic obstructive pulmonary disease	4
The need to consider market access for pharmaceutical investment decisions: a primer	4
Matching-adjusted indirect comparisons of diroximel fumarate, ocrelizumab and interferon beta-1a for relapsing multiple sclerosis	4
Letter in reply: network meta-analysis for indirect comparison of lanadelumab and for the treatment of hereditary angioedema	4
Potential policy reforms to strengthen the accelerated approval pathway	4
Budesonide/formoterol versus salmeterol/fluticasone for asthma in children: an effectiveness and safety analysis	4
Comparing the outcomes and costs of cardiac monitoring with implantable loop recorders and mobile cardiac outpatient telemetry following stroke using real-world evidence	4
Resource utilization and economic outcomes following repetitive transcranial magnetic stimulation for treatment-resistant depression: a retrospective observational analysis	4
Val (EU) xit: do we need an international ISPOR value flower?	4
Semaglutide treatment for obesity in teenagers: a plain language summary of the STEP TEENS research study	4
Impact of comparative effectiveness research on Medicare coverage of direct oral anticoagulants	4
Impact analysis of expanded access to ketamine for treatment-resistant depression	4
Comparing the efficacy of cipaglucosidase alfa plus miglustat with other enzyme replacement therapies for late-onset Pompe disease: a network meta-analysis utilizing patient-level and aggregate data	4